{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lutetium lu 177 dotatate","pembrolizumab"]],"indication":"Merkel cell carcinoma","name":"iPRRT","nct_id":"NCT05583708","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=iprrt-nct05583708. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"iPRRT","arms":[{"description":"All patients will receive pembrolizumab once every 6 weeks + Lutetium Lu177 dotatate once every 2 months\n\nPembrolizumab Cycle=6 weeks (for up to 2 years) Lutetium Lu177 dotatate Cycle=2 months (4 doses total)","label":"Experimental: Pembrolizumab + Lutetium Lu177","type":"EXPERIMENTAL"}],"collaborators":["Hoosier Cancer Research Network"],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Merkel Cell Carcinoma"],"enrollment":{"count":18,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Lutetium Lu 177 dotatate","otherNames":["PRRT","Lutathera"],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Weill Medical College of Cornell University","official_title":"A Single Arm Study With Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Immunotherapy for Patients With Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2023-08-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","url":"https://clinicaltrials.gov/study/NCT05583708"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/iprrt-nct05583708"}